Literature DB >> 34979073

Synergistic Effects of Phage-Antibiotic Combinations against Citrobacter amalonaticus.

Prasanth Manohar1,2, Madhav Madurantakam Royam3, Belinda Loh1, Bulent Bozdogan4, Ramesh Nachimuthu3, Sebastian Leptihn1,5,6.   

Abstract

Non-antibiotic alternative treatments to combat the increasing number of infections caused by multidrug resistant bacteria are urgently needed. In recent years, bacteriophages have reemerged to potentially replace or complement the role of antibiotics, as bacterial viruses have the ability to inactivate pathogens. This study aimed to evaluate the synergy of phage-antibiotic combinations. A Citrobacter amalonaticus isolate was used in this study together with the phage MRM57. Eight different antibiotics with different mechanisms of action were used in combination with the phage to study the impact of the combination treatment on the minimal inhibitory concentrations. We found that antibiotic concentration dependent synergism exists, albeit at different extents, with very low numbers of phages. This demonstrates the use of phages as an adjuvant with a sublethal concentration of antibiotics as an effective therapeutic strategy.

Entities:  

Keywords:  Citrobacter spp.; Phage therapy; bacteriophage; fractional inhibitory concentration; phage−antibiotic synergy; synergistic effect

Mesh:

Substances:

Year:  2022        PMID: 34979073     DOI: 10.1021/acsinfecdis.1c00117

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  5 in total

1.  Synergistic Effects of Bacteriophage vB_Eco4-M7 and Selected Antibiotics on the Biofilm Formed by Shiga Toxin-Producing Escherichia coli.

Authors:  Agnieszka Necel; Sylwia Bloch; Gracja Topka-Bielecka; Agata Janiszewska; Aleksandra Łukasiak; Bożena Nejman-Faleńczyk; Grzegorz Węgrzyn
Journal:  Antibiotics (Basel)       Date:  2022-05-25

Review 2.  Essential Topics for the Regulatory Consideration of Phages as Clinically Valuable Therapeutic Agents: A Perspective from Spain.

Authors:  Roberto Vázquez; Roberto Díez-Martínez; Pilar Domingo-Calap; Pedro García; Diana Gutiérrez; Maite Muniesa; María Ruiz-Ruigómez; Rafael Sanjuán; María Tomás; María Ángeles Tormo-Mas; Pilar García
Journal:  Microorganisms       Date:  2022-03-26

Review 3.  Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.

Authors:  Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Zuzanna Drulis-Kawa; Kathryn Cater; Petar Knežević; Cyprian Winogradow; Karolina Amaro; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Justyna Rękas; Andrzej Górski
Journal:  J Biomed Sci       Date:  2022-03-30       Impact factor: 8.410

4.  Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis-A Case Report.

Authors:  Karlis Racenis; Dace Rezevska; Monta Madelane; Ervins Lavrinovics; Sarah Djebara; Aivars Petersons; Juta Kroica
Journal:  Front Med (Lausanne)       Date:  2022-04-25

5.  A Lysozyme Murein Hydrolase with Broad-Spectrum Antibacterial Activity from Enterobacter Phage myPSH1140.

Authors:  Nachimuthu Ramesh; Prasanth Manohar; Kandasamy Eniyan; Loganathan Archana; Sudarsanan Athira; Belinda Loh; Long Ma; Sebastian Leptihn
Journal:  Antimicrob Agents Chemother       Date:  2022-08-11       Impact factor: 5.938

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.